Characterization and application of in situ curcumin/ZNP hydrogels for periodontitis treatment

BMC Oral Health. 2024 Mar 28;24(1):395. doi: 10.1186/s12903-024-04054-7.

Abstract

Background: Periodontitis is a chronic inflammatory disease that occurs in tooth-supporting tissues. Controlling inflammation and alleviating periodontal tissue destruction are key factors in periodontal therapy. This study aimed to develop an in situ curcumin/zinc oxide (Cur/ZNP) hydrogel and investigate its characteristics and effectiveness in the treatment of periodontitis.

Methods: Antibacterial activity and cytotoxicity assays were performed in vitro. To evaluate the effect of the in situ Cur/ZNP hydrogel on periodontitis in vivo, an experimental periodontitis model was established in Sprague‒Dawley rats via silk ligature and inoculation of the maxillary first molar with Porphyromonas gingivalis. After one month of in situ treatment with the hydrogel, we examined the transcriptional responses of the gingiva to the Cur/ZNP hydrogel treatment and detected the alveolar bone level as well as the expression of osteocalcin (OCN) and osteoprotegerin (OPG) in the periodontal tissues of the rats.

Results: Cur/ZNPs had synergistic inhibitory effects on P. gingivalis and good biocompatibility. RNA sequencing of the gingiva showed that immune effector process-related genes were significantly induced by experimental periodontitis. Carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1), which is involved in the negative regulation of bone resorption, was differentially regulated by the Cur/ZNP hydrogel but not by the Cur hydrogel or ZNP hydrogel. The Cur/ZNP hydrogel also had a stronger protective effect on alveolar bone resorption than both the Cur hydrogel and the ZNP hydrogel.

Conclusion: The Cur/ZNP hydrogel effectively inhibited periodontal pathogenic bacteria and alleviated alveolar bone destruction while exhibiting favorable biocompatibility.

Keywords: P. Gingivalis; Bone loss; Curcumin; Zinc oxide nanoparticles.

MeSH terms

  • Alveolar Bone Loss* / drug therapy
  • Alveolar Bone Loss* / metabolism
  • Alveolar Bone Loss* / prevention & control
  • Animals
  • Curcumin* / pharmacology
  • Curcumin* / therapeutic use
  • Disease Models, Animal
  • Hydrogels / therapeutic use
  • Organometallic Compounds*
  • Periodontitis* / metabolism
  • Porphyromonas gingivalis
  • Pyridines*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Curcumin
  • pyrithione zinc
  • Hydrogels
  • Organometallic Compounds
  • Pyridines